815 related articles for article (PubMed ID: 17898288)
1. Protective immunity against ocular herpes infection and disease induced by highly immunogenic self-adjuvanting glycoprotein D lipopeptide vaccines.
Bettahi I; Nesburn AB; Yoon S; Zhang X; Mohebbi A; Sue V; Vanderberg A; Wechsler SL; BenMohamed L
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4643-53. PubMed ID: 17898288
[TBL] [Abstract][Full Text] [Related]
2. Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response.
Bettahi I; Zhang X; Afifi RE; BenMohamed L
Viral Immunol; 2006; 19(2):220-36. PubMed ID: 16817765
[TBL] [Abstract][Full Text] [Related]
3. Lipopeptide epitopes extended by an Nepsilon-palmitoyl-lysine moiety increase uptake and maturation of dendritic cells through a Toll-like receptor-2 pathway and trigger a Th1-dependent protective immunity.
Zhu X; Ramos TV; Gras-Masse H; Kaplan BE; BenMohamed L
Eur J Immunol; 2004 Nov; 34(11):3102-14. PubMed ID: 15368273
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic immunization with a mixture of herpes simplex virus 1 glycoprotein D-derived “asymptomatic” human CD8+ T-cell epitopes decreases spontaneous ocular shedding in latently infected HLA transgenic rabbits: association with low frequency of local PD-1+ TIM-3+ CD8+ exhausted T cells.
Khan AA; Srivastava R; Chentoufi AA; Geertsema R; Thai NT; Dasgupta G; Osorio N; Kalantari M; Nesburn AB; Wechsler SL; BenMohamed L
J Virol; 2015 Jul; 89(13):6619-32. PubMed ID: 25878105
[TBL] [Abstract][Full Text] [Related]
5. A novel HLA (HLA-A*0201) transgenic rabbit model for preclinical evaluation of human CD8+ T cell epitope-based vaccines against ocular herpes.
Chentoufi AA; Dasgupta G; Christensen ND; Hu J; Choudhury ZS; Azeem A; Jester JV; Nesburn AB; Wechsler SL; BenMohamed L
J Immunol; 2010 Mar; 184(5):2561-71. PubMed ID: 20124097
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of a DNA vaccine encoding herpes simplex virus type 1 (HSV-1) glycoprotein D in decreasing ocular disease severity following corneal HSV-1 challenge.
Frye TD; Chiou HC; Hull BE; Bigley NJ
Arch Virol; 2002 Sep; 147(9):1747-59. PubMed ID: 12209314
[TBL] [Abstract][Full Text] [Related]
7. Protection against herpes simplex virus-induced eye disease after vaccination with seven individually expressed herpes simplex virus 1 glycoproteins.
Ghiasi H; Bahri S; Nesburn AB; Wechsler SL
Invest Ophthalmol Vis Sci; 1995 Jun; 36(7):1352-60. PubMed ID: 7775113
[TBL] [Abstract][Full Text] [Related]
8. Local and systemic B cell and Th1 responses induced following ocular mucosal delivery of multiple epitopes of herpes simplex virus type 1 glycoprotein D together with cytosine-phosphate-guanine adjuvant.
Nesburn AB; Ramos TV; Zhu X; Asgarzadeh H; Nguyen V; BenMohamed L
Vaccine; 2005 Jan; 23(7):873-83. PubMed ID: 15603887
[TBL] [Abstract][Full Text] [Related]
9. Exacerbation of murine herpes simplex virus-mediated stromal keratitis by Th2 type T cells.
Jayaraman S; Heiligenhaus A; Rodriguez A; Soukiasian S; Dorf ME; Foster CS
J Immunol; 1993 Nov; 151(10):5777-89. PubMed ID: 8228262
[TBL] [Abstract][Full Text] [Related]
10. Rectal immunization generates protective immunity in the female genital tract against herpes simplex virus type 2 infection: relative importance of myeloid differentiation factor 88.
Tengvall S; O'Hagan D; Harandi AM
Antiviral Res; 2008 Jun; 78(3):202-14. PubMed ID: 18276020
[TBL] [Abstract][Full Text] [Related]
11. Contributions of antibody and T cell subsets to protection elicited by immunization with a replication-defective mutant of herpes simplex virus type 1.
Morrison LA; Knipe DM
Virology; 1997 Dec; 239(2):315-26. PubMed ID: 9434723
[TBL] [Abstract][Full Text] [Related]
12. Lipid-containing mimetics of natural triggers of innate immunity as CTL-inducing influenza vaccines.
Lau YF; Deliyannis G; Zeng W; Mansell A; Jackson DC; Brown LE
Int Immunol; 2006 Dec; 18(12):1801-13. PubMed ID: 17077175
[TBL] [Abstract][Full Text] [Related]
13. Effect of immunization with herpes simplex virus type-1 (HSV-1) glycoprotein D (gD) plus the immune enhancer GPI-0100 on infection with HSV-1 or HSV-2.
Quenelle DC; Collins DJ; Marciani DJ; Kern ER
Vaccine; 2006 Mar; 24(10):1515-22. PubMed ID: 16288820
[TBL] [Abstract][Full Text] [Related]
14. Preventive effect of local plasmid DNA vaccine encoding gD or gD-IL-2 on herpetic keratitis.
Inoue T; Inoue Y; Nakamura T; Yoshida A; Takahashi K; Inoue Y; Shimomura Y; Tano Y; Fujisawa Y; Aono A; Hayashi K
Invest Ophthalmol Vis Sci; 2000 Dec; 41(13):4209-15. PubMed ID: 11095617
[TBL] [Abstract][Full Text] [Related]
15. IL-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1-type CD4+ T cell-mediated protective immunity against herpes simplex virus-2 challenge.
Sin JI; Kim JJ; Arnold RL; Shroff KE; McCallus D; Pachuk C; McElhiney SP; Wolf MW; Pompa-de Bruin SJ; Higgins TJ; Ciccarelli RB; Weiner DB
J Immunol; 1999 Mar; 162(5):2912-21. PubMed ID: 10072541
[TBL] [Abstract][Full Text] [Related]
16. A Herpes Simplex Virus Type 1 Human Asymptomatic CD8+ T-Cell Epitopes-Based Vaccine Protects Against Ocular Herpes in a "Humanized" HLA Transgenic Rabbit Model.
Srivastava R; Khan AA; Huang J; Nesburn AB; Wechsler SL; BenMohamed L
Invest Ophthalmol Vis Sci; 2015 Jun; 56(6):4013-28. PubMed ID: 26098469
[TBL] [Abstract][Full Text] [Related]
17. Recombinant herpes simplex virus type 1 (HSV-1) codelivering interleukin-12p35 as a molecular adjuvant enhances the protective immune response against ocular HSV-1 challenge.
Osorio Y; Ghiasi H
J Virol; 2005 Mar; 79(6):3297-308. PubMed ID: 15731224
[TBL] [Abstract][Full Text] [Related]
18. Immunization with DNA vaccine expressing herpes simplex virus type 1 gD and IL-21 protects against mouse herpes keratitis.
Hu K; He X; Yu F; Yuan X; Hu W; Liu C; Zhao F; Dou J
Immunol Invest; 2011; 40(3):265-78. PubMed ID: 21204603
[TBL] [Abstract][Full Text] [Related]
19. Identification of novel immunodominant CD4+ Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity.
BenMohamed L; Bertrand G; McNamara CD; Gras-Masse H; Hammer J; Wechsler SL; Nesburn AB
J Virol; 2003 Sep; 77(17):9463-73. PubMed ID: 12915561
[TBL] [Abstract][Full Text] [Related]
20. Nasal and skin delivery of IC31(®)-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes.
Wizel B; Persson J; Thörn K; Nagy E; Harandi AM
Vaccine; 2012 Jun; 30(29):4361-8. PubMed ID: 22682292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
